Phase 3 Study Finds Dupilumab Reduces COPD Exacerbations in Patients With Type 2 Inflammation

In the phase 3 BOREAS study of patients with chronic obstructive pulmonary disease (COPD) and type 2 inflammation, patients treated with dupilumab experienced fewer COPD exacerbations, improved lung function, and improved quality of life compared with patients given a placebo.

Related Keywords

Washington , United States , American , , American Thoracic Society International Conference , New England Journal , Thoracic Society International Conference , Respiratory Questionnaire , Evaluating Respiratory Symptoms , Wats 2023 , American Thoracic Society Conference News , Dupilumab ,